BERLIN, December 10, 2007 - By submitting its clinical study application, Berlin-based biotechnology company MOLOGEN today achieved an important milestone in the product development of its highly innovative immunomodulator dSLIM®. Phase Ib and IIa studies for investigating the safety and effectiveness of dSLIM® for use against various cancer diseases are planned. MOLOGEN expects to receive the study approval from the relevant authorities during the first quarter of 2008. The clinical studies are to be performed firstly in two well-known German cancer centers.
